60 x 257 cm. (23.6 x 101.2 in.) ...

GlobalData's Nancy Jaser said the decision is a blow ... of contracting other hospital acquired infections," she said. "Spero Therapeutics' tebipenem Hbr is a first-in-class oral carbapenem ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and... CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...